A S, Ludwig H, Schuch G, Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line therapy of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):66371. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al: K-ras mutations and advantage from cetuximab in sophisticated colorectal cancer. N Engl J Med 2008, 359(17):1757765. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, Erdkamp FLG, Vos AH, van Groeningen CJ, Sinnige HAM, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360(six):56372. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27(five):67280. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166169. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al: KRAS mutations as an independent prognostic element in patients with sophisticated colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):37479. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al: KRAS wild-type state predicts survival and is linked to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19(3):50815. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations in the BRAF gene in human cancer. Nature 2002, 417(6892):94954. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108113. Pinto P, Rocha P, Veiga I, Guedes J, Pinheiro M, Peixoto A, Pinto C, Fragoso M, Sanches E, Araujo A, et al: Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer.Chloroprocaine hydrochloride Cancer Genet 2011, 204(eight):43946.Olutasidenib Lungu O, Wright TC Jr, Silverstein S: Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis.PMID:23695992 Mol Cell Probes 1992, 6(two):14552. Pearson H, Stirling D: DNA extraction from tissue. Procedures Mol Biol 2003, 226:334. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C: High-resolution melting evaluation for fast detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008, 130(two):24753. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ: Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by highresolution amplicon melting analysis. Hum Pathol 2005, 36(five):48693. Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauemhofer T, Samonigg H, Hoefler G, Dandachi N: Evaluation of high-resolution melting evaluation as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009, 11(two):14047. The catalogue of somatic mutations in cancer. http://www.sanger.ac.uk/.